Merck said Wednesday it would buy COPD drugmaker Verona Pharma for $10 billion. The news sent Verona stock flying.

Former Senior Trump Health Official Urges Focus on Innovative "Upstream" Approaches that Disrupt Current Paradigm of Costly Chronic Care ...

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease in more than a decade.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant's portfolio of chronic obstructive pulmonary disease treatments with Verona Pharma's ...

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an approximately $10 billion deal. Merck said Wednesday that one of ...

A comprehensive meta-analysis of over 4.3 million adults shows e-cigarette use is associated with significantly higher odds ...

Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in ...

COPD, or chronic obstructive pulmonary disease, affects more than 30 million Americans, yet many have never heard of it. COPD ...

Broadens global development program for verekitug into third indication, strengthening pipeline across severe respiratory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP), severe ...

Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris, ...